Cargando…

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years. DESIGN: Systematic review and meta-analysis. D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Faizan, Rahman, Alvi, Carrier, Marc, Kearon, Clive, Weitz, Jeffrey I, Schulman, Sam, Couturaud, Francis, Eichinger, Sabine, Kyrle, Paul A, Becattini, Cecilia, Agnelli, Giancarlo, Brighton, Timothy A, Lensing, Anthonie W A, Prins, Martin H, Sabri, Elham, Hutton, Brian, Pinede, Laurent, Cushman, Mary, Palareti, Gualtiero, Wells, George A, Prandoni, Paolo, Büller, Harry R, Rodger, Marc A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651066/ https://www.ncbi.nlm.nih.gov/pubmed/31340984 http://dx.doi.org/10.1136/bmj.l4363

Ejemplares similares

Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis
por: Khan, Faizan, et al.
Publicado: (2017)

Screening for cancer in unprovoked venous thromboembolism
por: Shivji, Salma, et al.
Publicado: (2019)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
por: Ageno, Walter, et al.
Publicado: (2021)

Circumstances of provoked recurrent venous thromboembolism: the Austrian study on recurrent venous thromboembolism
por: Puhr, Hannah C., et al.
Publicado: (2019)

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It
por: Palareti, Gualtiero
Publicado: (2012)

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials
por: Boutitie, Florent, et al.
Publicado: (2011)

Genetic Risk Profiling Associated with Recurrent Unprovoked Venous Thromboembolism
por: Hodeib, Hossam, et al.
Publicado: (2021)

Cost‐minimization analysis of venous thromboembolism diagnosis: Comparison of standalone imaging with a strategy incorporating D‐dimer for exclusion of venous thromboembolism
por: Verma, Karan, et al.
Publicado: (2017)

Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?
por: Moodley, Otto, et al.
Publicado: (2015)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

Outcomes in infants with unprovoked venous thromboembolism: A retrospective cohort study
por: Whitworth, Hilary, et al.
Publicado: (2023)

Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis
por: van Es, Nick, et al.
Publicado: (2017)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
por: Weitz, Jeffrey I., et al.
Publicado: (2020)

Management of Patients With Unprovoked Venous Thromboembolism: An Evidence-Based and Practical Approach
por: Marcucci, Maura, et al.
Publicado: (2013)

Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism
por: Jara-Palomares, Luis, et al.
Publicado: (2018)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Case Report: Unprovoked venous thromboembolism in a young adult male
por: Dhabhar, Jeyhan, et al.
Publicado: (2019)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

d‐Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model
por: Eichinger, Sabine, et al.
Publicado: (2014)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Risk of venous thromboembolism during rehabilitation of patients with spinal cord injury
por: Eichinger, Sabine, et al.
Publicado: (2018)

Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Prediction of Recurrent Venous Thromboembolism by Clot Lysis Time: A Prospective Cohort Study
por: Traby, Ludwig, et al.
Publicado: (2012)

Venous thromboembolism and COVID-19
por: Bertoletti, L., et al.
Publicado: (2020)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

The prevalence and clinical manifestation of hereditary thrombophilia in Korean patients with unprovoked venous thromboembolisms
por: Lee, Su Yeon, et al.
Publicado: (2017)

Long‐Term Effects of Unprovoked Venous Thromboembolism on Mortality and Major Cardiovascular Events
por: Chang, Wei‐Ting, et al.
Publicado: (2017)

Exploring Opportunities for Primary Prevention of Unprovoked Venous Thromboembolism: Ready for Prime Time?
por: Folsom, Aaron R., et al.
Publicado: (2020)

Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients
por: Becattini, Cecilia, et al.
Publicado: (2020)

Management of venous thromboembolism: an update
por: Piran, Siavash, et al.
Publicado: (2016)

COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism
por: Han, Donghee, et al.
Publicado: (2016)

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis
por: Lopes, Luciane Cruz, et al.
Publicado: (2014)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7a2ciohan1eudkefv8stvrdlln